Cancer Genetics, Inc. (NasdaqCM:CGIX) announced that it has entered into a securities purchase agreement with certain institutional and accredited investors for private placement of 2,758,624 common shares at a price of $3.625 per share for gross proceeds of $10,000,012 on January 28, 2021. The company will also issue 2,758,624 warrants exercisable at $3.50 per share, immediately until August 3, 2026. The transaction is expected to close on or about February 1, 2021, subject to customary closing conditions. The company will receive net proceeds of $8,900,000 in the transaction. The securities to be issued are subject to exemption provided under Section 4(a)(2) of the Securities Act of 1933, as amended and Regulation D.